Addendum
Angiotensin II acetate (refractory hypotension in distributive shock) - Addendum to Commission A21-95
Report documents
-
Addendum
Angiotensin II acetate (refractory hypotension in distributive shock) - Addendum to Commission A21-95
Dossier assessment
Indication:
Refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite appropriate restoration of volume and use of catecholamines or other available vasoconstrictive therapies
Result of dossier assessment:
Unchanged after addendum:
Added benefit not proven.
Additional information
Federal Joint Committee (G-BA)
2022-01-06 A G-BA decision was published.
Project details
- Project no.
- A21-147
- Commission
- Commission awarded on 23.11.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Angiotensin II acetate (hypotension) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed